AstraZeneca Annual Report and Form 20-F Information 2011

Consolidated Statement of Financial Positionat 31 DecemberAssetsNon-current assetsProperty, plant and equipment 7 6,425 6,957 7,307Goodwill 8 9,862 9,871 9,889Intangible assets 9 10,980 12,158 12,226Derivative financial instruments 15 342 324 262Other investments 10 201 211 184Deferred tax assets 4 1,514 1,475 1,29229,324 30,996 31,160Current assetsInventories 11 1,852 1,682 1,750Trade and other receivables 12 8,754 7,847 7,709Other investments 10 4,248 1,482 1,484Derivative financial instruments 15 25 9 24Income tax receivable 1,056 3,043 2,875Cash and cash equivalents 13 7,571 11,068 9,91823,506 25,131 23,760Total assets 52,830 56,127 54,920LiabilitiesCurrent liabilitiesInterest-bearing loans and borrowings 14 (1,990) (125) (1,926)Trade and other payables 16 (8,975) (8,661) (8,687)Derivative financial instruments 15 (9) (8) (90)Provisions 17 (1,388) (1,095) (1,209)Income tax payable (3,390) (6,898) (5,728)(15,752) (16,787) (17,640)Non-current liabilitiesInterest-bearing loans and borrowings 14 (7,338) (9,097) (9,137)Deferred tax liabilities 4 (2,735) (3,145) (3,247)Retirement benefit obligations 18 (2,674) (2,472) (3,354)Provisions 17 (474) (843) (477)Other payables 16 (385) (373) (244)(13,606) (15,930) (16,459)Total liabilities (29,358) (32,717) (34,099)Net assets 23,472 23,410 20,821EquityCapital and reserves attributable to equity holders of the CompanyShare capital 20 323 352 363Share premium account 3,078 2,672 2,180Capital redemption reserve 139 107 94Merger reserve 433 433 433Other reserves 19 1,379 1,377 1,392Retained earnings 19 17,894 18,272 16,19823,246 23,213 20,660Non-controlling interests 226 197 161Total equity 23,472 23,410 20,821The Financial Statements from page 142 to 191 were approved by the Board on 2 February 2012 and were signed on its behalf byDavid R BrennanDirectorSimon LowthDirectorNotes2011$m2010$m2009$mFinancial StatementsAstraZeneca Annual Report and Form 20-F Information 2011 Financial Statements 143